Skip to main content
. 2022 Apr 28;15:471–478. doi: 10.2147/OTT.S272197

Figure 2.

Figure 2

Proposed treatment algorithm for patients with metastatic HER2-positive breast cancer.

Notes: *Preferred. Patients with CNS involvement must be evaluated for local therapy. TDxd and tucatinib+trastuzumab+capecitabine are preferred agents when CNS penetration of a systemic drug is desirable.

Abbreviations: THP, taxane, trastuzumab and pertuzumab; TDM1, ado-trastuzumab emtansine; TDxd, fam-trastuzumab deruxtecan.